(Israel21c) Abigail Klein Leichman - CollPlant, an Israeli regenerative medicine company focused on 3D bioprinting of tissues and organs, signed a license, development and commercialization agreement with United Therapeutics Corporation of Maryland for 3D bioprinted lung transplants. CollPlant has developed proprietary recombinant human collagen (rhCollagen) derived from engineered tobacco plants, as well as BioInk technology. BioInk includes a soft-tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds.
2018-11-08 00:00:00Full ArticleBACK Visit the Daily Alert Archive